Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/sciences-de-la-vie/theranostic-approach-for-pancreatic-cancer/descriptif_4200072
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=4200072

0 article 

 Frais de port 0,01€*

Exclusivité web : à partir de 35 euros d’achat, frais de port à 1 centime pour les expéditions vers la France métropolitaine, la Suisse et l’UE avec Colissimo ou GLS

Theranostic Approach for Pancreatic Cancer

Langue : Anglais

Coordonnateurs : Nagaraju Ganji Purnachandra, Ahmad Sarfraz

Couverture de l’ouvrage Theranostic Approach for Pancreatic Cancer

Theranostic Approach for Pancreatic Cancer modulates the biologic properties of stroma in pancreatic cancer by targeting the several chemotherapy resistance mechanisms to impede their malignant property through introducing new strategies and drugs for tackling the disease. It brings information about ongoing research as well as clinical data about pancreatic cancer and provides detailed descriptions about diagnostic and therapeutic options for easy understanding. The book discusses several topics related to pancreatic cancer, such as stem cells, drug resistance and pancreatic tumor microenvironment, the latest developments in chemotherapy for metastatic cancer and chemoprevention, and epigenome as a therapeutic strategy.

Additionally, it encompasses a discussion on theranostic clinical applications for personalized treatment and management of pancreatic cancer. The book is a valuable resource for cancer researchers, oncologists, and several members of the biomedical field who need to understand more about the diagnosis and treatment of pancreatic cancer.

1. Biology, pathophysiology and epidemiology of pancreatic cancer2. Diagnosis of pancreatic cancer 3. Current knowledge on drug resistance and therapeutic approaches to eliminate pancreatic cancer stem cells4. Drug resistance and microenvironment in pancreatic cancer 5. The role of tumor microenvironment in the metastasis of pancreatic cancer and immunotherapy 6. Latest developments in chemotherapy for metastatic pancreatic cancer 7. Genetic manipulations with chemotherapy in pancreatic cancer 8. Genetic predisposition for pancreatic cancer9. Pancreatic cancer resistance to chemotherapy: Resensitization strategies using resveratrol10. Anti-cancer activity of a small molecule, tolfenamic acid: An emphasis on pancreatic cancer11. Targeting the epigenome as a therapeutic strategy for pancreatic tumors - Non-coding RNAs and chromatin remodelers 12. Pancreatic cancer chemoprevention: A review on molecular pathways involved in carcinogenesis and targeting with terpenoids, a new potential anti-tumor drugs13. Meta-analysis on MTHFR polymorphisms and pancreatic cancer susceptibility 14. Therapeutic vaccines for pancreatic cancer 15. Epidermal growth factor receptor role in pancreatic cancer 16. Recent advances in molecular diagnostics and therapeutic targets for pancreatic cancer

Cancer researchers, medical scientists, clinicians, graduate students

Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books in Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).
Prof. Ahmad S is Director of Clinical Research at AdventHealth Cancer Institute (AHCI), Orlando, FL, USA. He earned his PhD in Biochemistry from North-Eastern Hill University, Shillong. Prof. Ahmad’s research focus is on the analyses of clinico-pathologic and surgical outcomes of oncology, hematology, and gastroenterology (GI) patients and to better understand the cellular/molecular mechanisms of cancer and related thromboembolic/hematologic disorders. Prof. Ahmad has published over 250 peer-reviewed scholarly research articles and book chapters, and over 400 scientific abstracts. He is a reviewer and has editorial responsibilities for several biomedical journals and books; and has received competitive research grants and national/international awards for his research contributions/accomplishments
  • Provides information on the roadblocks of chemotherapy in patients with newly diagnosed and metastatic pancreatic cancer<
  • Discusses treatment options available currently and prospective options for the future
  • Focuses especially on stroma, tumor microenvironment, stem cells, stellate cells, transcription factors, growth factors, and important signaling pathways as already tested types of treatment